# | Title | Journal | Year | Citations |
---|
1 | Chronic inflammation and cancer | Oncology | 2002 | 350 |
2 | Treatment of metastatic melanoma: an overview | Oncology | 2009 | 297 |
3 | NCCN Practice Guidelines for Cancer-Related Fatigue | Oncology | 2000 | 199 |
4 | Cancer stem cells: implications for cancer therapy | Oncology | 2014 | 187 |
5 | Understanding and treating triple-negative breast cancer | Oncology | 2008 | 179 |
6 | Financial toxicity, Part I: a new name for a growing problem | Oncology | 2013 | 177 |
7 | Managing toxicities of high-dose interleukin-2 | Oncology | 2002 | 158 |
8 | Progress toward guidelines for the management of fatigue | Oncology | 1998 | 153 |
9 | Challenges of Rural Cancer Care in the United States | Oncology | 2015 | 138 |
10 | NCI SEER public-use data: applications and limitations in oncology research | Oncology | 2009 | 129 |
11 | Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA) | Oncology | 2000 | 106 |
12 | Measuring quality of life today: methodological aspects | Oncology | 1990 | 103 |
13 | Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective | Oncology | 2005 | 103 |
14 | Radiation-induced lung injury. Assessment, management, and prevention | Oncology | 2008 | 103 |
15 | Antiangiogenic therapy for cancer: current and emerging concepts | Oncology | 2005 | 98 |
16 | Chronic inflammation and cancer: the role of the mitochondria | Oncology | 2011 | 97 |
17 | Managing thrombocytopenia associated with cancer chemotherapy | Oncology | 2015 | 96 |
18 | NCCN practice guidelines for the management of psychosocial distress. National Comprehensive Cancer Network | Oncology | 1999 | 87 |
19 | Obesity and cancer: the risks, science, and potential management strategies | Oncology | 2005 | 86 |
20 | Treatment of metastatic pancreatic adenocarcinoma: a review | Oncology | 2014 | 81 |
21 | Quality of life: what is it? How should it be measured? | Oncology | 1988 | 80 |
22 | Pharmacology, pharmacokinetics, and practical applications of bortezomib | Oncology | 2004 | 78 |
23 | Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae | Oncology | 2007 | 77 |
24 | General guidelines for the management of older patients with cancer | Oncology | 2000 | 76 |
25 | Epigenetics in cancer: what's the future? | Oncology | 2011 | 76 |
26 | Management of cancer in the elderly | Oncology | 2006 | 75 |
27 | Health literacy, communication, and treatment decision-making in older cancer patients | Oncology | 2009 | 73 |
28 | Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges | Oncology | 2008 | 72 |
29 | Neurocognitive dysfunction in cancer patients | Oncology | 2000 | 72 |
30 | Current surgical management of metastatic spinal disease | Oncology | 2000 | 72 |
31 | Immune targeting in breast cancer | Oncology | 2015 | 72 |
32 | Giving honest information to patients with advanced cancer maintains hope | Oncology | 2010 | 71 |
33 | The natural history of hormone receptor-positive breast cancer | Oncology | 2012 | 70 |
34 | The biology of integrins | Oncology | 2007 | 69 |
35 | Recurrent epithelial ovarian cancer: an update on treatment | Oncology | 2013 | 68 |
36 | Prognostic and predictive markers for the new immunotherapies | Oncology | 2014 | 68 |
37 | Management of brain metastases | Oncology | 1999 | 67 |
38 | Management of liver metastases from colorectal cancer | Oncology | 2006 | 66 |
39 | Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma | Oncology | 2002 | 65 |
40 | The Growing Challenge of Young Adults With Colorectal Cancer | Oncology | 2017 | 65 |
41 | General and statistical hierarchy of appropriate biologic endpoints | Oncology | 2006 | 62 |
42 | CEA monitoring in colorectal cancer. What you should know | Oncology | 2006 | 62 |
43 | Obesity and breast cancer | Oncology | 2011 | 62 |
44 | PI3K Inhibitors: Understanding Toxicity Mechanisms and Management | Oncology | 2017 | 62 |
45 | Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers | Oncology | 2006 | 61 |
46 | Integrins and cancer | Oncology | 2007 | 58 |
47 | Psychological and social aspects of breast cancer | Oncology | 2008 | 58 |
48 | Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer | Oncology | 2016 | 58 |
49 | Cervical lymph node metastases--diagnostic, therapeutic, and prognostic implications | Oncology | 1990 | 57 |
50 | Management of small-cell lung cancer: incremental changes but hope for the future | Oncology | 2008 | 56 |